Know Cancer

or
forgot password

PET Using Hormone Receptor Ligands in Breast Cancer


N/A
18 Years
N/A
Open (Enrolling)
Both
Breast Cancer

Thank you

Trial Information

PET Using Hormone Receptor Ligands in Breast Cancer


Inclusion Criteria:



- Male and Female patients

- Aged 18 or older at the time of breast cancer diagnosis

- Patients with invasive breast cancer at least 1 cm in size. Patients who have had a
prior surgical excision are eligible provided there is a residual of at least a 1 cm
area suspected on imaging studies.

- Histopathologic review at MSKCC confirming diagnosis of invasive breast cancer
(ductal, lobular, or inflammatory breast cancer).

- Patients who are operative candidates. Patient will have surgery to include either
mastectomy or lumpectomy. Radiologic assisted excisions such as needle localization
are also eligible.

- Patients with bilateral breast cancer are eligible.

- Patients with metastatic cancer, provided they need surgical biopsy.

- Patients who are undergoing sentinel node mapping (day before or sameday mapping).

- Patient must sign informed consent.

Exclusion Criteria:

- Previous or concurrent malignancy (except basal and squamous skin cancer and stage 0
cervical cancer)

- Patients who are pregnant or nursing

- Patients unable to tolerate PET or PET/CT

- Patients with known active infection, autoimmune or inflammatory disease such as
sarcoidosis, and rheumatoid arthritis.

- Patients with non invasive breast cancer such as DCIS.

- Patients who have received prior radiation therapy to the affected breast.

- Patients who have received prior chemotherapy, including neoadjuvant chemotherapy or
hormonal therapy for breast cancer.

- Patients living in a residential care or correctional facility.

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

To use estrogen-like ligands labeled with positron emitters to preoperatively evaluate the estrogen receptor (ER) status of breast cancer on PET imaging.

Outcome Time Frame:

conclusion of the study

Safety Issue:

No

Principal Investigator

Mary Gemignani, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Institutional Review Board

Study ID:

05-088

NCT ID:

NCT00647790

Start Date:

November 2006

Completion Date:

November 2013

Related Keywords:

  • Breast Cancer
  • PET imaging
  • invasive breast cancer
  • Breast Neoplasms

Name

Location

Memorial Sloan Kettering Cancer CenterNew York, New York  10021